NHS patients with rare blood disorders gain access to Ultomiris
Around 270 people with PNH and 160 people with aHUS will be eligible for the new treatment
Read More
Tag: eculizumab
EU expands approval of Alexion’s Soliris
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read More
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More
NHS funding cleared for new specialised treatments
Three new specialised treatments are now to be made available on the NHS for patients in England after being initially rejected for funding back in December, NHS England has announced.
Read More
NHS England orders national service to handle Soliris
NHS England has announced plans to establish a national service to treat the ultra-rare kidney condition Atypical Haemolytic Uraemic Syndrome (aHUS), and the administration of Alexion’s high-cost Soliris.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
